- Home
- CLB vs PRTC Comparison
CLB vs PRTC Comparison
Compare CLB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- PRTC
- Stock Information
- Founded
- CLB 1936
- PRTC 2015
- Country
- CLB United States
- PRTC United States
- Employees
- CLB N/A
- PRTC N/A
- Industry
- CLB
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- PRTC Health Care
- Exchange
- CLB Nasdaq
- PRTC Nasdaq
- Market Cap
- CLB 482.5M
- PRTC 413.5M
- IPO Year
- CLB 1995
- PRTC N/A
- Fundamental
- Price
- CLB $12.48
- PRTC $16.08
- Analyst Decision
- CLB Hold
- PRTC Buy
- Analyst Count
- CLB 2
- PRTC 1
- Target Price
- CLB $12.50
- PRTC $45.00
- AVG Volume (30 Days)
- CLB 490.5K
- PRTC 5.2K
- Earning Date
- CLB 10-22-2025
- PRTC 08-28-2025
- Dividend Yield
- CLB 0.32%
- PRTC N/A
- EPS Growth
- CLB 23.99
- PRTC N/A
- EPS
- CLB 0.62
- PRTC 0.20
- Revenue
- CLB $517,378,000.00
- PRTC $6,391,000.00
- Revenue This Year
- CLB N/A
- PRTC N/A
- Revenue Next Year
- CLB $2.23
- PRTC N/A
- P/E Ratio
- CLB $20.36
- PRTC $7.45
- Revenue Growth
- CLB 0.70
- PRTC 1265.60
- 52 Week Low
- CLB $9.72
- PRTC $13.30
- 52 Week High
- CLB $21.83
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- CLB 61.63
- PRTC 38.80
- Support Level
- CLB $12.07
- PRTC $15.75
- Resistance Level
- CLB $13.21
- PRTC $16.75
- Average True Range (ATR)
- CLB 0.47
- PRTC 0.57
- MACD
- CLB 0.15
- PRTC -0.11
- Stochastic Oscillator
- CLB 71.64
- PRTC 8.50
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.